ReviewMetabolites2023

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis.

Shizuya Yamashita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.